125 related articles for article (PubMed ID: 37004748)
1. Which trial do we need? How to treat Pseudomonas aeruginosa bacteraemia-proposal for an umbrella randomized controlled trial.
Gilboa M; van Duin D; Yahav D
Clin Microbiol Infect; 2023 Jul; 29(7):829-831. PubMed ID: 37004748
[No Abstract] [Full Text] [Related]
2. Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.
Grupper M; Sutherland C; Nicolau DP
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739780
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam.
Hernández-Tejedor A; Merino-Vega CD; Martín-Vivas A; Ruiz de Luna-González R; Delgado-Iribarren A; Gabán-Díez Á; Temprano-Gómez I; de la Calle-Pedrosa N; González-Jiménez AI; Algora-Weber A
Infection; 2017 Feb; 45(1):115-117. PubMed ID: 27670678
[TBL] [Abstract][Full Text] [Related]
4. Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for Pseudomonas aeruginosa Bloodstream Infection: A Multisite Retrospective Study.
Babich T; Naucler P; Valik JK; Giske CG; Benito N; Cardona R; Rivera A; Pulcini C; Abdel Fattah M; Haquin J; Macgowan A; Grier S; Gibbs J; Chazan B; Yanovskay A; Ben Ami R; Landes M; Nesher L; Zaidman-Shimshovitz A; McCarthy K; Paterson DL; Tacconelli E; Buhl M; Mauer S; Rodriguez-Bano J; Morales I; Oliver A; Ruiz De Gopegui E; Cano A; Machuca I; Gozalo-Marguello M; Martinez Martinez L; Gonzalez-Barbera EM; Alfaro IG; Salavert M; Beovic B; Saje A; Mueller-Premru M; Pagani L; Vitrat V; Kofteridis D; Zacharioudaki M; Maraki S; Weissman Y; Paul M; Dickstein Y; Leibovici L; Yahav D
Clin Infect Dis; 2020 May; 70(11):2270-2280. PubMed ID: 31323088
[TBL] [Abstract][Full Text] [Related]
5. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
Humphries RM; Hindler JA; Wong-Beringer A; Miller SA
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993338
[TBL] [Abstract][Full Text] [Related]
6. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
[TBL] [Abstract][Full Text] [Related]
7.
Goodlet KJ; Nicolau DP; Nailor MD
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
[TBL] [Abstract][Full Text] [Related]
8. Antibiotic therapy and clinical outcomes of Pseudomonas aeruginosa (PA) bacteraemia.
Tan SH; Teng CB; Ng TM; Lye DC
Ann Acad Med Singap; 2014 Nov; 43(11):526-34. PubMed ID: 25523856
[TBL] [Abstract][Full Text] [Related]
9. Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV.
Evans SR; Tran TTT; Hujer AM; Hill CB; Hujer KM; Mediavilla JR; Manca C; Domitrovic TN; Perez F; Farmer M; Pitzer KM; Wilson BM; Kreiswirth BN; Patel R; Jacobs MR; Chen L; Fowler VG; Chambers HF; Bonomo RA;
Clin Infect Dis; 2019 May; 68(11):1823-1830. PubMed ID: 30239599
[TBL] [Abstract][Full Text] [Related]
10. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins.
Zobell JT; Waters CD; Young DC; Stockmann C; Ampofo K; Sherwin CM; Spigarelli MG
Pediatr Pulmonol; 2013 Feb; 48(2):107-22. PubMed ID: 22949297
[TBL] [Abstract][Full Text] [Related]
11. Mutation-driven β-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals.
Castanheira M; Mills JC; Farrell DJ; Jones RN
Antimicrob Agents Chemother; 2014 Nov; 58(11):6844-50. PubMed ID: 25182652
[TBL] [Abstract][Full Text] [Related]
12. Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: Facing the perfect storm.
Recio R; Villa J; Viedma E; Orellana MÁ; Lora-Tamayo J; Chaves F
Int J Antimicrob Agents; 2018 Aug; 52(2):172-179. PubMed ID: 29621591
[TBL] [Abstract][Full Text] [Related]
13. A propensity score-matched analysis of the impact of minimum inhibitory concentration on mortality in patients with Pseudomonas aeruginosa bacteremia treated with cefepime or ceftazidime.
Ratliff AR; Gentry CA; Williams RJ
Diagn Microbiol Infect Dis; 2017 Apr; 87(4):376-381. PubMed ID: 28087171
[TBL] [Abstract][Full Text] [Related]
14. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
[TBL] [Abstract][Full Text] [Related]
15. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany.
Seifert H; Körber-Irrgang B; Kresken M;
Int J Antimicrob Agents; 2018 Feb; 51(2):227-234. PubMed ID: 28705666
[TBL] [Abstract][Full Text] [Related]
16. Use of Ceftolozane/Tazobactam in the Treatment of Multidrug-resistant Pseudomonas aeruginosa Bloodstream Infection in a Pediatric Leukemia Patient.
Aitken SL; Kontoyiannis DP; DePombo AM; Bhatti MM; Tverdek FP; Gettys SC; Nicolau DP; Nunez CA
Pediatr Infect Dis J; 2016 Sep; 35(9):1040-2. PubMed ID: 27254038
[TBL] [Abstract][Full Text] [Related]
17. Liver abscess caused by multidrug-resistant Pseudomonas aeruginosa treated with colistin; a case report and review of the literature.
Yaita K; Sameshima I; Takeyama H; Matsuyama S; Nagahara C; Hashiguchi R; Moronaga Y; Tottori N; Komatsu M; Oshiro Y; Yamaguchi Y
Intern Med; 2013; 52(12):1407-12. PubMed ID: 23774557
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint.
Tam VH; Gamez EA; Weston JS; Gerard LN; Larocco MT; Caeiro JP; Gentry LO; Garey KW
Clin Infect Dis; 2008 Mar; 46(6):862-7. PubMed ID: 18279040
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
Kim HS; Park BK; Kim SK; Han SB; Lee JW; Lee DG; Chung NG; Cho B; Jeong DC; Kang JH
BMC Infect Dis; 2017 Jul; 17(1):500. PubMed ID: 28716109
[TBL] [Abstract][Full Text] [Related]
20. Time above the MIC of Piperacillin-Tazobactam as a Predictor of Outcome in Pseudomonas aeruginosa Bacteremia.
Tannous E; Lipman S; Tonna A; Hector E; Hussein Z; Stein M; Reisfeld S
Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32482679
[No Abstract] [Full Text] [Related]
[Next] [New Search]
